Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and medical devices in China. The company is involved in the production and supply of pharmaceutical products in the fields of chronic diseases, including cardiovascular and cerebrovascular diseases, diabetes, oncology, osteoporosis, anti-infective diseases, and chronic kidney ...
Shenzhen Salubris Pharmaceuticals reported revenue of 4.01 billion CNY for fiscal year 2024, up 19.2% from fiscal year 2023, and net income of 601.57 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 1.07 billion CNY, up 12.3% from a year before. Its largest business segment, Pharmaceutical Manufacturing, brought in 91% of segment revenue in fiscal year 2025.
Figures from company filings; latest fiscal year ended December 31, 2024.
No profile data available.